AGIOS PHARMACEUTICALS, INC. — Revenue by Fiscal Year
15 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/01052148-8d63-4819-b966-b8a3c9f51808/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $54.0M | 2025-01-01 – 2025-12-31 | evidence 0001439222-26-000025 |
| FY 2024 | $36.5M | 2024-01-01 – 2024-12-31 | evidence 0001439222-25-000009 |
| FY 2023 | $26.8M | 2023-01-01 – 2023-12-31 | evidence 0001439222-24-000035 |
| FY 2022 | $14.2M | 2022-01-01 – 2022-12-31 | evidence 0001439222-23-000039 |
| FY 2021 | $0 | 2021-01-01 – 2021-12-31 | evidence 0001439222-23-000039 |
| FY 2020 | $0 | 2020-01-01 – 2020-12-31 | evidence 0001439222-23-000039 |
| FY 2019 | $117.9M | 2019-01-01 – 2019-12-31 | evidence 0001439222-20-000014 |
| FY 2018 | $94.4M | 2018-01-01 – 2018-12-31 | evidence 0001439222-19-000004 |
| FY 2017 | $43.0M | 2017-01-01 – 2017-12-31 | evidence 0001439222-19-000004 |
| FY 2016 | $69.9M | 2016-01-01 – 2016-12-31 | evidence 0001439222-19-000004 |
| FY 2015 | $59.1M | 2015-01-01 – 2015-12-31 | evidence 0001439222-18-000004 |
| FY 2014 | $65.4M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-060046 |
| FY 2013 | $25.5M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-104521 |
| FY 2012 | $25.1M | 2012-01-01 – 2012-12-31 | evidence 0001193125-14-104521 |
| FY 2011 | $21.8M | 2011-01-01 – 2011-12-31 | evidence 0001193125-14-104521 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
AGIOS PHARMACEUTICALS, INC. — all facts · Net Income · Operating Income